216 related articles for article (PubMed ID: 15732048)
1. [Cancer after kidney transplantation].
Sandrini S; Setti G; Bossini N; Maiorca P
G Ital Nefrol; 2004; 21 Suppl 26():S67-73. PubMed ID: 15732048
[TBL] [Abstract][Full Text] [Related]
2. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports.
Iaria G; Anselmo A; De Luca L; Manuelli M; Lucchesi C; Tariciotti L; Monaco A; Sforza D; Nigro F; Abruzzese E; Tisone G
Transplant Proc; 2007; 39(6):2036-7. PubMed ID: 17692685
[TBL] [Abstract][Full Text] [Related]
3. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.
Manuelli M; De Luca L; Iaria G; Tatangelo P; Sforza D; Perrone L; Bellini MI; Angelico R; Anselmo A; Tisone G
Transplant Proc; 2010 May; 42(4):1314-6. PubMed ID: 20534289
[TBL] [Abstract][Full Text] [Related]
4. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
[TBL] [Abstract][Full Text] [Related]
5. Regression of post-transplant Kaposi's sarcoma using sirolimus.
Kolhe N; Mamode N; Van der Walt J; Pattison J
Int J Clin Pract; 2006 Nov; 60(11):1509-12. PubMed ID: 16787440
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
Garcia VD; Bonamigo Filho JL; Neumann J; Fogliatto L; Geiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Ferrera des Santos A; Roithmann S
Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217
[TBL] [Abstract][Full Text] [Related]
7. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
[TBL] [Abstract][Full Text] [Related]
8. Development of lymphoproliferative disease after liver transplantation.
Marqués E; Jiménez C; Manrique A; Vallejo GH; Clemares M; Ortega P; Moreno E
Transplant Proc; 2008 Nov; 40(9):2988-9. PubMed ID: 19010169
[TBL] [Abstract][Full Text] [Related]
9. Minimizing the risk of posttransplant malignancy.
Campistol JM
Transplantation; 2009 Apr; 87(8 Suppl):S19-22. PubMed ID: 19384182
[TBL] [Abstract][Full Text] [Related]
10. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
Pascual J
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder.
Cullis B; D'Souza R; McCullagh P; Harries S; Nicholls A; Lee R; Bingham C
Am J Kidney Dis; 2006 May; 47(5):e67-72. PubMed ID: 16632009
[TBL] [Abstract][Full Text] [Related]
12. [Presentation of cancers in recipients of a solid-organ transplant].
Lampreabe I; Gómez-Ullate P; Amenábar JJ; Zárraga S; Gaínza FJ; Urbizu JM
Nefrologia; 2001; 21(6):528-37. PubMed ID: 11881422
[No Abstract] [Full Text] [Related]
13. The role of mTOR inhibitors in the management of posttransplant malignancy.
Monaco AP
Transplantation; 2009 Jan; 87(2):157-63. PubMed ID: 19155967
[TBL] [Abstract][Full Text] [Related]
14. [Cancer after kidney transplantation and immunosuppression].
Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Antova Z; Spasovski G; Vlckova-Laskovska M; Zografski G
Ann Urol (Paris); 2000 Oct; 34(5):336-9. PubMed ID: 11144722
[TBL] [Abstract][Full Text] [Related]
15. Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases.
Bichari W; Bartiromo M; Mohey H; Afiani A; Burnot A; Maillard N; Sauron C; Thibaudin D; Mehdi M; Mariat C; Alamartine E; Berthoux F
Transplant Proc; 2009 Mar; 41(2):672-3. PubMed ID: 19328953
[TBL] [Abstract][Full Text] [Related]
16. Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease.
Bocchi EA; Higuchi ML; Vieira ML; Stolf N; Bellotti G; Fiorelli A; Uip D; Jatene A; Pileggi F
J Heart Lung Transplant; 1998 Apr; 17(4):399-405. PubMed ID: 9588585
[TBL] [Abstract][Full Text] [Related]
17. [Skin cancer in renal transplant recipients].
Mangino M; Schena FP
G Ital Nefrol; 2010; 27 Suppl 50():S75-80. PubMed ID: 20922700
[TBL] [Abstract][Full Text] [Related]
18. [Lymphoproliferative disease and cancer in the transplant patient].
Herreros J; Flórez S; Echevarría JR; Fernández AL; Pardo Mindán FJ
Rev Esp Cardiol; 1995; 48 Suppl 7():129-34. PubMed ID: 8775827
[TBL] [Abstract][Full Text] [Related]
19. [Kaposi's sarcoma in 2 patients after renal transplantation].
Gómez Uribe JI; Arango Acosta JL
Med Cutan Ibero Lat Am; 1984; 12(3):215-9. PubMed ID: 6384692
[TBL] [Abstract][Full Text] [Related]
20. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients.
Libertiny G; Watson CJ; Gray DW; Welsh KI; Morris PJ
Br J Surg; 2001 Oct; 88(10):1330-4. PubMed ID: 11578286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
